Opus Genetics Inc (IRD) Stock Price, Quote & News

Company Profile

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs...

Industry: Biotechnology

Sector: Healthcare

Phone: 984 884 6030

Website: opusgtx.com

Address:

8 Davis Drive, Suite 220, Durham, United States

TruthTooPower Apr. 2 at 11:13 AM

$IRD!!! Cantor Fitzgerald Has It Just Right For Us Keeping Up With Target of an NHOD!!!

0 · Reply

signaljumper Mar. 30 at 5:38 PM

$IRD i think we will See 3.90 or a little bit lower again, this area will BE the Last Chance to get in cheap. The Indices will Slide lower in the coming days. Max pain will BE Arp nd 3.29$

0 · Reply

erevnon Mar. 30 at 12:14 PM

Cantor Fitzgerald initiates coverage on Opus Genetics $IRD at Overweight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

TheAliAbdul Mar. 27 at 8:44 PM

$IRD healthy consolidation after a big run up, needs to keep this $4.30-$4.50 level.

0 · Reply

TruthTooPower Mar. 27 at 5:08 PM

$IRD!!! Buy Low Sell High!!!

0 · Reply

TruthTooPower Mar. 27 at 5:07 PM

$IRD!!! 🤓🤓🤓

0 · Reply

TruthTooPower Mar. 25 at 10:09 AM

$IRD!!! These Changes are a Testament to the Confidence this Company has given me Day One! The Company is making these decisions from a position of Strength, and they know they will be Rewarded Accordingly!

0 · Reply

alexquick123 Mar. 25 at 2:19 AM

$IRD damn that’s crazy work, no wonder the stock pumped. I want to stay in for the drug release but increasing the board and shares is BS

0 · Reply

alexquick123 Mar. 25 at 2:17 AM

$IRD they about to have 20 heads on their board . Shit makes zero sense they keep adding people.

0 · Reply

yft212 Mar. 23 at 9:17 PM

$IRD I am NOT voting in favor of diluting the stock!

2 · Reply

Opus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026

Mar 10, 2026, 7:00 AM EDT - 26 days ago

Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Mar 3, 2026, 8:00 AM EST - 4 weeks ago

Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Feb 27, 2026, 10:10 AM EST - 5 weeks ago

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Feb 25, 2026, 6:59 AM EST - 5 weeks ago

Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Feb 22, 2026, 9:35 PM EST - 5 weeks ago

Opus Genetics: Asymmetric Upside With LCA5 And BEST1

Feb 13, 2026, 7:30 AM EST - 7 weeks ago

Opus Genetics Announces $25 Million Private Placement

Feb 2, 2026, 8:00 AM EST - 2 months ago

Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Jan 27, 2026, 7:00 AM EST - 2 months ago

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Jan 15, 2026, 3:26 PM EST - 2 months ago

Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 3 months ago

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

Dec 16, 2025, 4:01 PM EST - 3 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 7:00 AM EST - 4 months ago

Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 9, 2025, 7:00 AM EST - 4 months ago

Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease

Nov 20, 2025, 8:00 AM EST - 4 months ago

Opus Genetics to Participate in Upcoming Investment Conferences

Nov 13, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Nov 12, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces $23 Million Registered Direct Offering

Nov 6, 2025, 7:00 AM EST - 5 months ago

Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease

Oct 14, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

Oct 2, 2025, 8:00 AM EDT - 6 months ago

Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025

Sep 30, 2025, 12:12 PM EDT - 6 months ago

Opus Genetics, Inc. - Special Call

Sep 30, 2025, 7:00 AM EDT - 6 months ago

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)

$Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Sep 4, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Appoints Rob Gagnon as Chief Financial Officer

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September

Aug 18, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1

Aug 13, 2025, 4:30 PM EDT - 8 months ago

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 23, 2025, 8:00 AM EDT - 9 months ago

Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness

Jul 3, 2025, 4:30 PM EDT - 9 months ago

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2025, 6:55 AM EDT - 10 months ago

Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Jun 23, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program

$Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions$

Jun 2, 2025, 8:00 AM EDT - 10 months ago

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions

May 15, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

May 6, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate

May 5, 2025, 8:00 AM EDT - 11 months ago

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision

Apr 11, 2025, 3:47 PM EDT - 1 year ago

Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Opus Genetics to Participate in Upcoming Investor Conference in April

Mar 31, 2025, 8:20 AM EDT - 1 year ago

Opus Genetics Announces Financial Results for Full Year 2024

Mar 21, 2025, 5:03 PM EDT - 1 year ago

Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics

Mar 21, 2025, 9:30 AM EDT - 1 year ago

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Mar 21, 2025, 9:11 AM EDT - 1 year ago

Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million

Mar 5, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Feb 26, 2025, 8:00 AM EST - 1 year ago

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Feb 18, 2025, 7:30 AM EST - 1 year ago

Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program

Feb 7, 2025, 9:15 AM EST - 1 year ago

Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.

XBI

TruthTooPower Apr. 2 at 11:13 AM

$IRD!!! Cantor Fitzgerald Has It Just Right For Us Keeping Up With Target of an NHOD!!!

0 · Reply

signaljumper Mar. 30 at 5:38 PM

$IRD i think we will See 3.90 or a little bit lower again, this area will BE the Last Chance to get in cheap. The Indices will Slide lower in the coming days. Max pain will BE Arp nd 3.29$

0 · Reply

erevnon Mar. 30 at 12:14 PM

Cantor Fitzgerald initiates coverage on Opus Genetics $IRD at Overweight rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

TheAliAbdul Mar. 27 at 8:44 PM

$IRD healthy consolidation after a big run up, needs to keep this $4.30-$4.50 level.

0 · Reply

TruthTooPower Mar. 27 at 5:08 PM

$IRD!!! Buy Low Sell High!!!

0 · Reply

TruthTooPower Mar. 27 at 5:07 PM

$IRD!!! 🤓🤓🤓

0 · Reply

TruthTooPower Mar. 25 at 10:09 AM

0 · Reply

alexquick123 Mar. 25 at 2:19 AM

$IRD damn that’s crazy work, no wonder the stock pumped. I want to stay in for the drug release but increasing the board and shares is BS

0 · Reply

alexquick123 Mar. 25 at 2:17 AM

$IRD they about to have 20 heads on their board . Shit makes zero sense they keep adding people.

0 · Reply

yft212 Mar. 23 at 9:17 PM

$IRD I am NOT voting in favor of diluting the stock!

2 · Reply

TruthTooPower Mar. 23 at 1:07 PM

$GRI!!! $INDP !!! $IRD !!! Get Ready To Rumble!!!

0 · Reply

QuantInsider Mar. 20 at 7:50 PM

$IRD taking a beating lately, down 4.7% today and 10.6% over the past week No fresh news, just pure sell-off action Options activity is all about those same-day deep ITM $2.5 calls with 500 contracts but nothing screams big moves Looks more like hedging than a real upside play If you're thinking of jumping in, keep it tight with risk limits This one's all about riding the volatility wave for now

0 · Reply

ifinitis Mar. 18 at 8:16 PM

$IRD Weak Hands taking profits..and.. Wall Street dropping to get in before it runs up! IMO. To be expected in hind site!

0 · Reply

TruthTooPower Mar. 18 at 5:45 PM

$IRD!!! Rock On Adding!!!

0 · Reply

McLarkin Mar. 17 at 3:48 PM

$OCGN well well - folks seem to notice these now, not quite another $IRD but certainly going for it in Retinal Gene Therapy - which feels one of the lowest risk and better probabilities of Gene Therapy Success...

0 · Reply

Atime2Buy Mar. 17 at 2:21 PM

$IRD people cant hold to save their @ss. this dip seems to be based solely on profit taking, good time to buy.

0 · Reply

ifinitis Mar. 16 at 9:05 PM

$IRD Looks good on saying good bye to $5.20 tomorrow! Oppenheimer initiated coverage with an outperform rating and a price target of $10.00.

0 · Reply

erevnon Mar. 16 at 3:56 PM

Oppenheimer initiates coverage on Opus Genetics $IRD at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

DARKP00L Mar. 16 at 2:47 PM

$IRD 10:22 on Mar. 16 2026 Oppenheimer Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10 #tradeideas

1 · Reply

Um8a123 Mar. 16 at 1:03 PM

$IRD Ready for next leg, $6:35

0 · Reply

erevnon Mar. 12 at 3:01 PM

Wedbush maintains Opus Genetics $IRD at Outperform and raises the price target from $8 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Tazdoc88 Mar. 12 at 2:06 PM

$IRD

0 · Reply

Market Cap	323.73M
Revenue (ttm)	14.20M
Net Income (ttm)	-49.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-349.23%
Debt to Equity Ratio	0.00

Volume	348,100
Avg Vol	1,025,786
Day's Range	N/A - N/A
Shares Out	71.15M
Stochastic %K	43%
Beta	0.52
Analysts	Strong Sell
Price Target	$9.93